Engineering adeno-associated viruses for clinical gene therapy

Area of Science:

• Biotechnology
• Molecular Biology
• Genetics

Background:

• Clinical gene therapy success is growing.
• Improved molecular understanding of diseases and gene delivery technologies are key drivers.
• Adeno-associated virus (AAV) vectors are prominent delivery systems, noted for safety and efficacy.

Purpose of the Study:

• To review the advancements in gene delivery technologies for clinical gene therapy.
• To highlight the role and potential of adeno-associated virus (AAV) vectors.
• To discuss the challenges and ongoing engineering efforts in AAV vector development.

Main Methods:

• Review of current literature on gene therapy and viral vector technologies.
• Analysis of the properties and applications of adeno-associated virus (AAV) vectors.
• Examination of strategies for engineering AAV vectors and genetic cargo.

Main Results:

• Adeno-associated virus (AAV) vectors have demonstrated significant safety and efficacy in clinical settings.
• One AAV-based therapy has received regulatory approval, marking a milestone.
• Current research focuses on overcoming limitations of AAV vectors for wider disease application.

Conclusions:

• Adeno-associated virus (AAV) vectors are a leading technology in clinical gene therapy.
• Continued engineering of AAV vectors and their genetic payloads is crucial for expanding therapeutic applications.
• Advances in AAV technology promise to address more genetic diseases effectively.